Psma-Hbed-Cc
Diagnosis
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSradiopharmaceuticalN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Diagnosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
L-HUPERZINE A Shanghai Mental Health Center | Phase 4 | BB |
Gilteritinib Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 | CCC |
Same molecule, other indications
Psma-Hbed-Cc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →